NorthStar Medical Radioisotopes, LLC, a global firm involved in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, and GE Healthcare recently announced the signing of an exclusive agreement for the manufacturing and distribution of iodine-123 (I-123) capsules in the United States. Under the contract’s terms, GE Healthcare’s Pharmaceutical Diagnostics unit will manufacture and supply NorthStar with I-123 capsules under the NorthStar label using a new, state-of-the-art production system at its facility in Arlington Heights, Ill. Upon receipt of the required regulatory approvals, NorthStar will retain exclusive U.S. marketing and distribution rights for these I-123 capsules, which will be available in 100µCi and 200µCi formulations.
To
read more please visit: